Peptide Therapeutics intermediate
Rimegepant - First-in-Human (NCT01434008)
First-in-human trial of rimegepant for migraine. This peptide or oligopeptide is studied for its biological activity, structure-activity relationships, and p...
By Encyclopeptide Editorial | 1 min read
rimegepant-first-in-human-nct01434008 peptide research
Overview
First-in-human trial of rimegepant for migraine.
Clinical Significance
This topic has important implications for peptide research and clinical applications.
References
- Encyclopeptide Database. “Rimegepant - First-in-Human (NCT01434008)” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Rimegepant - First-in-Human (NCT01434008) with interactive quizzes on Wikipept.
Take a Quiz on Wikipept